Literature DB >> 6889694

Penicillamine-induced myasthenia gravis: effects of penicillamine on acetylcholine receptor.

C T Bever, H W Chang, A S Penn, I A Jaffe, E Bock.   

Abstract

Autoimmune diseases, including myasthenia gravis, occur in patients treated with D-penicillamine. Because D-penicillamine might induce autoantibodies by the mechanism of antigenic alteration, we studied the reaction of D-penicillamine with purified acetylcholine receptor from Torpedo californica. We found that brief exposure to D-penicillamine resulted in its covalent attachment to two receptor subunits, alpha (40,000 daltons) and gamma (59,000 daltons), presumably by reduction and formation of mixed disulfides. Furthermore, D-penicillamine treatment resulted in a dramatic modification of the equilibrium acetylcholine binding properties of both purified receptor and receptor-rich membrane fragments.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6889694     DOI: 10.1212/wnl.32.10.1077

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

2.  Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis.

Authors:  S J Tzartos; E Morel; A Efthimiadis; A F Bustarret; J D'Anglejan; A A Drosos; H A Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

3.  Penicillamine induced myasthenia reactivated by gold.

Authors:  A P Moore; A C Williams; P Hillenbrand
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-21

4.  Myasthenic pseudo-internuclear ophthalmoplegia due to penicillamine.

Authors:  J George; E G Spokes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-09       Impact factor: 10.154

5.  Thyroid function and immune profile in rheumatoid arthritis. A controlled study.

Authors:  A P Andonopoulos; V Siambi; M Makri; M Christofidou; C Markou; A G Vagenakis
Journal:  Clin Rheumatol       Date:  1996-11       Impact factor: 2.980

6.  Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis?

Authors:  Jian Rong Sheng; Liang Cheng Li; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Muscle Nerve       Date:  2009-08       Impact factor: 3.217

7.  D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence?

Authors:  A P Andonopoulos; E Terzis; E Tsibri; C A Papasteriades; T Papapetropoulos
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

Review 8.  Ocular myasthenia gravis after D-penicillamine administration.

Authors:  L J Katz; R L Lesser; J R Merikangas; J P Silverman
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

Review 9.  Pathophysiological basis in the management of myasthenia gravis: a mini review.

Authors:  Aiswarya Binu; Sarath S Kumar; Uma Devi Padma; Krishnadas Madhu
Journal:  Inflammopharmacology       Date:  2022-01-21       Impact factor: 4.473

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.